Clinical Trial

A Study on the Effect of CGM Alone on Glycemic Metrics in Type 2 Diabetes Patients Not Using Insulin, Without Additional Interventions

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study evaluates the effect of using a real-time continuous glucose monitoring (CGM) system on blood sugar control in people with type 2 diabetes who do not use insulin. Participants will wear a CGM device (CareSens Air) for a total of two weeks. During the first week, the device will be set to "blinded mode," meaning participants cannot see their glucose readings. During the second week, the device will be switched to "unblinded mode," allowing participants to view their glucose levels and trends in real-time. The study aims to determine if simply seeing real-time glucose data can help patients improve their blood sugar control (such as increasing the time their blood sugar is in the target range) without receiving additional structured education on diet or exercise. Researchers will compare the glucose data collected during the blinded week with the data from the unblinded week.
Trial Details
NCT Number NCT07298850
Lead Sponsor Kangbuk Samsung Hospital
Collaborators: i-SENS, Inc.
Conditions Continuous Glucose Monitoring, Type 2 Diabetes
Enrollment 120 participants
Start Date 2024-09-30
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-23